First meeting “Cystic echinococcosis in Chile, update in alternatives for control and diagnostics in animals and humans”

Abstract

This report summarizes the outcomes of a meeting on cystic echinococcosis (CE) in animals and humans in Chile held in Santiago, Chile, between the 21st and 22nd of January 2016. The meeting participants included representatives of the Departamento de Zoonosis, Ministerio de Salud (Zoonotic Diseases Department, Ministry of Health), representatives of the Secretarias Regionales del Ministerio de Salud (Regional Department of Health, Ministry of Health), Instituto Nacional de Desarrollo Agropecuario (National Institute for the Development of Agriculture and Livestock, INDAP), Instituto de Salud Pública (National Institute for Public Health, ISP) and the Servicio Agrícola y Ganadero (Animal Health Department, SAG), academics from various universities, veterinarians and physicians. Current and future CE control activities were discussed. It was noted that the EG95 vaccine was being implemented for the first time in pilot control programmes, with the vaccine scheduled during 2016 in two different regions in the South of Chile. In relation to use of the vaccine, the need was highlighted for acquiring good quality data, based on CE findings at slaughterhouse, previous to initiation of vaccination so as to enable correct assessment of the efficacy of the vaccine in the following years. The current world’s-best-practice concerning the use of ultrasound as a diagnostic tool for the screening population in highly endemic remote and poor areas was also discussed.

Erratum to: First meeting “Cystic echinococcosis in Chile, update in alternatives for control and diagnostics in animals and humans”

“…Unfortunately, the original version of this article [1] contained an error. Within the author list, “Ministry of Health, SAG and other organizations attending the meeting” and “a list of collaborators” was erroneously included.…”

Trends and correlates of cystic echinococcosis in Chile: 2001–2012

“…In Chile, echinococcosis has been classified as a mandatory notifiable disease since 2000 [ 3 ] and is the leading cause of hospital admissions for parasitic diseases [ 4 – 6 ]. The estimated hospital discharge rate associated with echinococcosis at the national level is estimated at 4.7–5.0 cases per 100,000 population, and approximately 2 cases per 100,000 inhabitants require surgical treatment, mainly affecting the working age group [ 7 – 8 ]. To date, AE has never been reported in Chile [ 6 ].…”

“…There are currently no official national programs for the control of E . granulosus in Chile, despite efforts in previous years [ 8 ]. Chile first established a CE control program in 1979, which was carried out by the Livestock and Agricultural Service.…”

“…However, due to implementation costs, the frequency of administrating praziquantel was reduced to twice a year. Overall, the program led to a 60–70% reduction in CE prevalence in sheep and dogs over a 27-year period (60% to 0.7% and 71% to 0.5% from 1978 to 2004, respectively) [ 7 – 8 , 13 – 14 ]. The program was dismantled in 2004.…”

Equinococosis quística músculo-esquelética primaria de evolución crónica

“…a equinococosis quística o hidatidosis es una zoonosis parasitaria producida por la larva del cestode Echinococcus granulosus. Es una infección re-emergente de amplia distribución mundial 1 , que integra el grupo de las enfermedades que la Organización Mundial de la Salud ha denominado enfermedades tropicales desatendidas (ETD) [2][3][4][5] . Echinococcus granulosus sensu stricto es la principal causa de equinococosis quística en la mayoría de los casos humanos y animales en el mundo y la especie más extendida dentro del complejo E. granulosus sensu lato.…”